anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
White adipose tissue (WAT) has been recognized as a fundamental and crucial organ of interest in research focusing on inflammation during obesity or aging. WAT is also proposed as a significant component of cholecalciferol and 25-hydroxyvitamin D (25(OH)D) storage, which participates in the decrease of 25(OH)D plasma levels reported during aging and obesity. In the present study, we evaluated WAT and plasma cholecalciferol and 25(OH)D content together with inflammatory status to highlight the putative relationship between vitamin D status and inflammatory process during aging alone or combined with obesity. Circulating cholecalciferol and 25(OH)D and the stored quantity of cholecalciferol and 25(OH)D in WAT were quantified in young and old mice fed a control or obesogenic diet. The inflammation was assessed by measuring plasma inflammatory cytokines, mRNA, and microRNAs inflammatory-associated in WAT. The combination of aging and obesity decreased 25(OH)D plasma levels but did not modify circulating inflammatory markers. A cumulative effect of aging and obesity was observed in WAT, with rising mRNA inflammatory cytokines, notably Ccl5 and Tnf. Interestingly, aging and obesity-associated were also characterized by increased inflammatory microRNA expression. The inflammatory parameters in WAT were negatively correlated with the plasma 25(OH)D but positively correlated with the quantity of cholecalciferol and 25(OH)D in WAT. These results support the cumulative effect of obesity and aging in aggravation of WAT inflammation and suggest that accumulation of cholecalciferol and 25(OH)D in WAT could constitute a mechanism to counteract WAT inflammation during aging and obesity.
Delirium is a syndrome characterized by failure of basic cognitive functions that affects approximately 20-50% of older surgical patients. Delirium during surgical recovery is associated with increased mortality, cognitive and functional decline, and prolonged hospitalization. In fact, 3-year survival rates for acutely hospitalized patients with delirium, and subsyndromal delirium, are both less than 50%. Older age is predictive of delirium after surgery, and with aging surgical populations, the incidence of postoperative delirium and related complications are likely to increase in the coming years.

Caffeine represents a novel, neurobiologically informed candidate intervention for reducing risk of early postoperative delirium. Caffeine promotes arousal via adenosine receptor antagonism and improves cognitive function concurrent with increased cortical cholinergic tone. Our preliminary data suggest that caffeine reduces risk of postanesthesia care unit (PACU) delirium in adult non-cardiac surgery patients by optimizing cortical dynamics for cognition. Caffeine also optimizes key neurocognitive processes that support information processing and may improve other, related aspects of clinical recovery, such as rebound headache in habitual caffeine users. The objective of this trial is to thus test the effects of caffeine on neurocognitive and clinical recovery after major surgery. Specifically, the primary hypothesis is that caffeine will reduce the incidence of postoperative delirium. The secondary objectives are to (1) test whether caffeine positively impacts the quality of postoperative recovery via validated patient-reported measures and (2) identify neural correlates of delirium and Mild Cognitive Impairment via advanced electroencephalographic (EEG) analysis.
Patients "responding" to treatment after 8 weeks of treatment: i.e. whose clinical evolution is beneficial.
PROBLEM TO BE SOLVED: To obtain sustained effects (slow release effects) of a pharmaceutically active ingredient on an adherend by laminating a supporting member having air permeability onto one surface of a tacky agent layer having micropores vertically passing therethrough on the whole surface and prepared by uniformly dispersing a highly water absorbing resin containing the pharmaceutically active ingredient in the tacky agent. SOLUTION: This tacky material in the case of, e.g. an adhesive tape is obtained by laminating a supporting material 1 having air permeability onto one surface of a tacky agent layer 2 and sticking a mold release treated substrate 3 to the other surface. The tacky agent layer 2 is formed from a dried tacky agent 2a prepared by uniformly dispersing a highly water absorbing resin containing a pharmaceutically active ingredient-containing aqueous medium in a solution of a raw material tacky agent in an organic solvent, and the tacky agent layer 2 is capable of facilitating the moister absorption and desorption of the highly water absorbing resin and has many micropores 2b vertically passing therethrough and capable of slowly releasing the pharmaceutically active ingredient onto the adherend surface.  The tacky agent 2a is preferably obtained by mixing the water absorbing resin containing the pharmaceutically active ingredient-containing aqueous medium in an amount of 20-50 pts.wt. based on 100 pts.wt. solution of the raw material tacky agent in the organic solvent.
Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of an agent that inhibits CD200. Such methods are useful in treating cancer.
The invention belongs to the field of gene engineering and particularly relates to an FREP (fibrinogen-related protein) of chlamys farreri with bacterial binding activity and preparation and application of the protein. The FREP protein of chlamys farreri is a CfFREP gene recombinant protein, the amino acid sequence of which is shown in SEQ ID NO. 1. The preparation comprises the following steps: amplifying the cDNA overall length of a CfFREP molecular gene of chlamys farreri; and carrying out pronucleus recombinant expression on a coding region of the CfFREP molecular gene. The recombinant protein provided by the invention is a CfFREP active molecule containing a FBG (fibrinogen) structural domain in chlamys farreri. The protein can be combined with molecules in various PAMPs (pathogen associated molecular patterns) and can be used as an immunopotentiator/adjuvant candidate molecule of shellfishes.
Liver fibrosis is a condition characterized by aberrant proliferation of connective tissue in the liver resulting from diverse etiological factors. G protein-coupled receptor GPR55 has recently been identified as a regulator of liver diseases. Herein, we report the discovery of a cyclic peptide P1-1 that antagonizes GPR55 and suppresses collagen secretion in hepatic stellate cells. The alanine scanning and docking study was carried out to predict the binding mode and allowed for further structural optimization of peptide antagonists for GPR55. The subsequent in vivo study demonstrated that P1-1 ameliorates CCl4-induce and MCD-diet-induce acute liver inflammation and fibrosis. Further study indicates that P1-1 reduces reactive oxygen species (ROS) production, attenuates ER stress, and inhibits mitochondria-associated hepatocyte apoptosis. In this work, we provided the first successful example of antagonizing GPR55 for liver inflammation and fibrosis, which validates GPR55 as a promising target for the treatment of liver fibrosis and affords a high-potent GPR55 antagonist P1-1 as a potential therapeutic candidate.
Despite its high prevalence, effective treatment for degenerative mitral regurgitation (MR) remains elusive. Although the mineralocorticoid-receptor antagonist spironolactone, in conjunction with renin-angiotensin-aldosterone system inhibitors, has been shown to reduce mortality in patients with heart failure with reduced ejection fraction, its efficacy in managing degenerative MR is uncertain. In this study, we aimed to compare the effectiveness of valsartan (a renin-angiotensin system inhibitor), spironolactone, and combination therapy in mitigating MR-induced myocardial dysfunction. Using a mini-invasive model of degenerative MR, we administered valsartan (31 mg/kg/d), spironolactone (80 mg/kg/d), or a combination of both to rats over a 4-week period. Serial echocardiography and pressure-volume loops were utilized to assess cardiac function and hemodynamics. Rats with degenerative MR treated with valsartan or spironolactone alone did not show significant improvement in myocardial dysfunction. In contrast, combination therapy resulted in significant improvement. Similarly, the pressure-volume relationship was significantly improved in rats treated with the combination therapy compared with that in rats treated with a single therapy. Mechanistically, combination therapy effectively suppressed circulating and cardiac expression of aldosterone- and apoptosis-associated proteins. Overall, combination treatment with valsartan and spironolactone significantly attenuated the degenerative MR-induced myocardial stress and dysfunction, suggesting a potential therapeutic avenue for managing degenerative MR-induced heart failure.
PURPOSE:To provide the titled drug containing guanosine monophosphate as an active component, exhibiting blood platelet coagulation suppressing effect, useful as a remedy for thrombosis, and having low toxicity. CONSTITUTION:The objective drug contains guanosine monophosphate (GMP) of formula (one of X, Y and Z is H2PO3 and the other two are H) as an active component. GMP is a known substance existing in the living body, and is present e.g. in the pancreas, liver, spleen, etc. It can be synthesized from guanosine existing in e.g. the spleen. GMP of formula exhibits strong activity to inhibit the thrombin-induced coagulation of blood platelet in vitro as well as by the animal (rabbit) experiment by oral and intravenous administration. Furthermore, it has extremely low toxicity and is administrable continuously for a long period, and accordingly, it is useful as a remedy for thrombosis.
The anterior cruciate ligament (ACL) is an important stabilizer of the knee. Orthopedic surgeons replace the torn ligament during ACL reconstruction surgery. Surgical trauma initiates an acute inflammatory response, including swelling and pain, that leads to restricted joint motion and loss of function. Because of the dynamic nature, complexity and redundancy of the chemical mediators of inflammation and pain and their pathways, no currently available single drug has sufficiently broad spectrum of activity to effectively inhibit the inflammatory process. OMS103 provides a multicomponent approach to controlling the inflammation induced by arthroscopic surgery. It delivers three active ingredients, each with distinct pharmacological activities, directly to the site of surgical procedures to preemptively block the inflammatory cascade induced by surgical trauma.
The invention discloses a traditional Chinese medicine used for treating coronary heart disease, and a preparation method thereof. The medicine is composed of the materials of typha latifolia, salvia miltiorrhiza, panax notoginseng, cucumber stem, kelp base, ligusticum, pilose asiabell root, cushaw stem and leaf, chrysanthemum flower, cushaw leaf, Mongolian snakegourd fruit, Szechwan lovage rhizome, zanthoxylum nitidum, prepared tuber fleeceflower root, Japanese pagodatree twig, epimedium, Japanese metaplexis pericarp, desertliving cistanche herb, tuckahoe, and honey. The traditional Chinese medicine provided by the invention is scientifically reasonably formulated, such that the functions of the materials provide a synergetic effect. With the medicine, heart function can be regulated; good treatment effect is provided for treating coronary heart disease, and side effect is low. Also, agricultural products such as cushaw stem and leaf, chrysanthemum flower, cushaw leaf, Mongolian snakegourd fruit, and the like in the raw materials have coronary heart disease treating functions. The cost is low, the materials are easy to obtain, and a treatment effect is significant. Also, various nutrients for human bodies can be provided, such that human physical fitness can be enhanced.
Reducing tobacco consumption is a major public health objective, with the prevalence of active smoking estimated in 2017 at 26.9% of the French population aged 18 to 25. The negative impact of passive smoking on children's health and development has been demonstrated by numerous studies, especially with regard to respiratory pathologies. Parental smoking is also a risk factor for active smoking in adolescence and adulthood (with an odds ratio of 1.72 if at least one of the two parents is a smoker). It has been shown that intervention with parents can reduce the number of children exposed to passive parental smoking by about 5%. The paediatrician's role is therefore to try to make parents aware of the consequences of tobacco consumption on their children's health and to encourage them to stop smoking. Minimal advice (simple, clear, written and oral information on the actors and means of helping to stop smoking) is the first step in triggering an attempt to stop smoking. The paediatrician seems to be a particularly influential actor since he intervenes at a time when parents are trying to improve their child's health. The minimum advice would have an effectiveness of 2-5% on smoking cessation in general. There is no data on the impact of this minimum advice when given by paediatricians. There are also no data on the current prevalence of smoking in France among parents of children with various chronic diseases, such as cystic fibrosis or diabetes. It is also necessary to describe the smoking habits of parents, as children's exposure and its impact on their health depends in particular on where their parents smoke.
Contact x-ray brachytherapy will be given applied after randomisation with a maximum interval of 14 weeks after finishing the neoadjuvant (chemo)radiation. Contact x-ray brachytherapy consists of three fractions of 30Gy per fraction applied to the tumour, with a 2 week interval between each boost. Response evaluation takes place every 3 months thereafter. Patients in whom a clinical complete response is detected during follow-up are offered a watch-and-wait approach; patients in whom an incomplete response or disease progression is noted, completion or salvage TME-surgery is advised.
PURPOSE:A coagulation accelerator of blood, containing an organopolysiloxane fluid having one or more monofunctional hydrocarbon groups having a hydroxyl or carboxylic acid group in one molecule as a principal agent, and capable of facilitating the blood chemical test by reducing the blood coagulation time. CONSTITUTION:A coagulation accelerator of blood, containing an organopolysiloxane fluid having at least one monofunctional hydrocarbon group containing a hydroxyl group, e.g. CH2OH, or monofunctional hydrocarbon group containing a carboxylic acid group, e.g. CH2CH2COOH, e.g. formulaI, II or III (R<1> is monofunctional hydrocarbon group contaning OH or COOH; R is monofunctional hydrocarbon group containing no OH or COOH; m is an integer >=0; n is an integer >=1; k is 1, 2 or 3; l is an integer 1-4; k+l=4) as a principal agent, and having a viscosity of 10-50,000cSt at 25 deg.C. The agent has a coagulation accelerating action on blood absent in the usual organopolysiloxane, and capable of reducing the time of standing required for the separation of blood serum.
The invention relates to a preparation method of a novel magnetic 5-fluorouracil carrying polylactic-co-glycolic acid (PLGA) material. The preparation method of the novel magnetic 5-fluorouracil carrying PLGA material comprises the following steps: adding nano particles into a PLGA solution, dissolving 5-fluorouracil into dimethyl sulfoxide (DMSO), adding 5-Fu DMSO solution into the PLGA solution, and carrying out ultrasonic treatment, so that oil in oil (O/O) emulsion is obtained; then adding the O/O emulsion into PVA aqueous solution saturated by 5-Fu, stirring for evaporating a solvent, solidifying microspheres, washing with deionized water, and performing freeze drying, so that the magnetic 5-Fu carrying PLGA microspheres are obtained. The obtained drug carrying microspheres are uniform in particle size, and the particle size is 100-500 microns. Drug loading capacity of the microspheres is high and can be 10%. Drug releasing rate is regulated by regulating ratio of LA to GA in PLGA. As magnetic nano particles are introduced, under the control action of an external magnetic field, the drug carrying microspheres can be concentrated in a tumour region, and drug concentration in the tumour region is increased, so that apoptosis of tumour cells is quick, and harm of anti-tumour drug to normal cells is reduced to minimum. The preparation method of the novel magnetic 5-fluorouracil carrying PLGA material is simple and practicable, raw materials can be industrially produced, and the preparation method of the novel magnetic 5-fluorouracil carrying PLGA material has good popularization and application values.
Fortification of staple foods with iron may be an effective method of addressing the problem of iron deficiency. Questions however remain of the type of iron fortificants to use, the appropriate fortification levels and suitable food vehicles. Cereals form attractive vehicles because they are widely consumed in parts of the world that bear a large burden of the iron deficiency problem. They are however high in phytates and would reduce the bioavailability of commonly used iron fortificants. Isotope studies have shown that even in the presence of phytates, iron from NaFeEDTA is relatively more bioavailable than that from other fortificant sources. Its efficacy has however not been assessed in human trials. Electrolytic iron, on the other hand is widely used and was legislated as the iron fortificant of choice in South Africa. Its efficacy in a high-phytate vehicle has also not been assessed. We have therefore undertaken to assess the efficacy of NaFeEDTA at two doses, as an iron fortificant in whole flour, and the efficacy of electrolytic iron at a dose similar to the high-dose NaFeEDTA. The results will contribute information on the suitability of these fortificants in whole maize flour, a food commonly consumed in sub-Saharan Africa.
All participants will receive Care4AD device.All reminders will be activated in the intervention group (IG). Essential activity daily living (ADL) tasks will be pre-programmed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
The aim of this study is to assess and compare a mindfulness low-intensity (4 weeks) psychological intervention for the treatment of depression in Primary Care between different groups: 1) a face-to-face mindfulness intervention in group format (10-12 people/group), 2) a control group which will received primary care TAU (usual medical treatment) and 3) the same mindfulness intervention applied by Information and Communication Technologies (ICTs) (Internet-based program). All participants in the two psychological intervention groups will also receive usual medical treatment managed by their general practitioner. Each group will be composed of 40 participants with a total sample of 120. The principal hypothesis is that face to face intervention will be more effective than TAU. Secondary hypothesis, are: 1) The online computerized program will be more effective than TAU; 2) The differences between face-to-face and online format will be analyzed. Finally, a qualitative study will be conducted in order to analyze the feasibility, acceptance, barriers and causes of drop-outs and success, expectations, experiences and attitudes that could be obstacles or facilitators in the interventions, both in patients and in health professionals. This study will allow us to understand the experiences of depressed patients with these interventions and their differences.
Pre-operative Continuous 5-FU, and Sorafenib with External Radiation Therapy. Dose level -1 will only be evaluated if dose level 1 exceeds MTD. The sorafenib and infusional 5-FU will only be given Day 1-5(Monday-Friday) with radiation only.
NEW MATERIAL:The compound of formula (R is H or CH3) (named as plumeric acid and methyl plumerate, respectively). USE:A carcinostatic agent. PREPARATION:Dried leaves of Brumellia actifolia Boyl are pulverized, extracted with 90% ethanol solution and concentrated under reduced pressure to obtain a crude extract. The extract is subjected to adsorption chromatography and eluted successively with water-methanol solvent. A fraction having strong growth-inhibiting activity against cultured cell of Yoshida sarcoma is selected from the obtained fractions and a crude crystal separated from the fraction is treated with ethyl acetate to separate into a component soluble in ethyl acetate and crude crystal hardly soluble in ethyl acetate. The former component is acetylated with acetic anhydride-pyridine, separated and purified by high- performance liquid chromatography, deacetylated to the original compound with 5% MeOH, KOH and the compound of formula is separated together with other two kinds of known substances.
BACKGROUND: Early diagnosis of prostate cancer is key to achieving a cure and its proper management leads to a good prognosis. In Ghana a large percentage of patients present with advanced disease and unusual presentations in these patients result in greater delay in the diagnosis thus worsening the outcomes.
CASE PRESENTATION: We present three African males with advanced prostate cancer who had delayed diagnosis. The first patient, a 64 year old male presented with ascites of 2 years duration with weight loss and no lower urinary tract symptoms, the second, a 69 year old man with end stage renal failure of 6 months duration and was receiving dialysis, the third case, an 87 year old man was managed for pulmonary tuberculosis after he presented with chronic cough and lower urinary tract symptoms. All patients eventually had a prostate specific antigen done which were elevated. Further investigations including prostate biopsies, abdominopelvic CT scans for case 1, abdominopelvic ultrasound, prostate biopsies and blood urea and electrolytes for case 2, prostate biopsies, chest and lumbosacral showed a diagnosis of metastatic prostate carcinoma, and all patients were managed with androgen deprivation. The second patient received additional radiotherapy.
CONCLUSION: A lack of knowledge of prostate cancer symptoms including unusual symptoms, can result in delayed diagnosis especially in regions of the world where a large number of patients present with advanced disease.